Tax Appeal 2021

Help CERA unlock the answers to AMD

Donate today and put hope in sight for the one in seven Australians over 50 with age-related macular degeneration (AMD). AMD is the leading cause of legal blindness in Australia.

Your tax-deductible donation helps our researchers make breakthroughs and innovations to transform our understanding and treatment of AMD.

There are currently no effective treatments for dry AMD, which is why our world-class macular research is so very important.


One in seven Australians over 50 will develop signs of age-related macular degeneration (AMD).

Donate today so our team of brilliant team of macular researchers can find new ways to diagnose, prevent and treat AMD – and give people like Win Murphy more moments with the ones they love.


“The first optometrist I saw was very blunt. ‘You’ve got AMD,’ she said. ‘You’re going to go blind. It’s as simple as that.’ I remember being absolutely devastated.”

“It continues to amaze me how far research into AMD has come, thanks to CERA. I don’t know where I’d be without it. Most probably blind, just like the optometrist said.”

– Win Murphy, diagnosed with AMD almost 25 years ago.

AMD research restores Win’s hope for the future

Win Murphy’s uncle once told her that ‘when the telephone lines go wobbly, you need to have your eyes checked’. So, when Win noticed her vision changing, she knew what was happening.

Win’s father and his four siblings had all been diagnosed with age-related macular degeneration (AMD). At 52, Win discovered she too had the early signs of the disease.

Understanding AMD

AMD is an eye disease that affects the macula – the central part of the retina at the back of the eye. The macula is full of light-sensitive cells that give us sharp central vision when we look straight ahead. In AMD, the cells in the macula gradually break down. This can lead to blurred central vision, making it hard to read, drive and recognise faces.

AMD is the leading cause of legal blindness in Australia. There are often no symptoms of AMD until the disease advances and vision is affected.

AMD can be ‘early-stage’ or ‘late-stage’. There are two forms of late-stage AMD:

  • Dry AMD – caused by a loss of cells in the macula.
  • Wet AMD – caused by abnormal blood vessels that grow under the retina and bleed. It is often more sudden and noticeable than dry AMD.


There are currently no effective treatments for dry AMD, which is why our world-class macular research is so very important.


Research holds the answers

Your support is helping brilliant researchers to drive exciting new breakthroughs in the treatment and prevention of AMD every single day – breakthroughs that were once deemed unachievable.

From artificial intelligence and laser studies to gene therapy and molecular biology, we use our world-class knowledge and expertise to turn discoveries made in the lab into real treatments for people like Win.

Our brilliant team of macular researchers are working hard to revolutionise how AMD is diagnosed, monitored and treated. They won’t stop until they have found effective ways to treat AMD and prevent its progression.

Your ongoing support empowers our researchers to lead the charge in modern medicine and one day find cures to restore sight.

Thank you for supporting our 2021 Tax Appeal

From everyone at CERA, we are sincerely grateful for your support of research with real-life impact.

Your support and commitment ensure that the work being undertaken by CERA’s remarkable team of clinician researchers in the macular team, led by Professor Robyn Guymer, can continue working to revolutionise how AMD is diagnosed, monitored, and treated.